Levy Adam D. sold $2K of ACRV
Levy Adam D. (Chief Financial Officer) sold 1,142 shares of Acrivon Therapeutics, Inc. (ACRV) at $1.57 on 2026-08-04.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market sale details (shares, price, total value, post-transaction holdings). The text does not include any company-specific operational or financial update.
Market read
Traders may monitor insider activity for sentiment, but this filing alone is unlikely to drive a durable repricing without additional fundamental catalysts.
What to watch
The article provides no context on total holdings, prior sales cadence, or whether the CFO had other compensation events; without that, interpreting signal strength is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for Acrivon Therapeutics, Inc.
Ticker impact
Acrivon Therapeutics CFO Levy Adam D. sold 1,142 shares in an open-market transaction at $1.57 on 2026-08-04, per Form 4.
Low near-term impact; any reaction is likely limited to sentiment/positioning rather than a new fundamental catalyst.
The filing is a routine Form 4 insider transaction with no 10b5-1 plan and no accompanying corporate event, guidance, or operational update in the text.
Market effects
Minimal; single insider sale does not indicate sector-wide change.
None indicated.
None indicated.
Counterpoint
Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; without a 10b5-1 plan, the sale still does not prove negative company outlook.
Key entities
- issuerAcrivon Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderLevy Adam D.
Chief Financial Officer who sold shares.
